|
1.
|
Barendsen GW: Dose fractionation, dose
rate and iso-effect relationships for normal tissue responses. Int
J Radiat Oncol Biol Phys. 8:1981–1997. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Barendsen GW: Mechanisms of cell
reproductive death and shapes of radiation dose-survival curves of
mammalian cells. Int J Radiat Biol. 57:885–896. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Barendsen GW: The relationships between
RBE and LET for different types of lethal damage in mammalian
cells: biophysical and molecular mechanisms. Radiat Res.
139:257–270. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Barendsen GW: Parameters of
linear-quadratic radiation dose-effect relationships: dependence on
LET and mechanisms of reproductive cell death. Int J Radiat Biol.
71:649–655. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Barendsen GW, van Bree C and Franken NAP:
Importance of cell proliferative state and potentially lethal
damage repair on radiation effectiveness: Implications for combined
tumor treatments (Review). Int J Oncol. 19:257–256. 2001.
|
|
6.
|
Franken NAP, van Bree C, Kipp JB and
Barendsen GW: Modification of potentially lethal damage in
irradiated Chinese hamster V79 cells after incorporation of
halogenated pyrimidines. Int J Radiat Biol. 72:101–109. 1997.
View Article : Google Scholar
|
|
7.
|
Franken NAP, Ten Cate R, van Bree C and
Haveman J: Induction of the early response protein EGR-1 in human
tumour cells after ionizing radiation is correlated with a
reduction of repair of lethal lesions and an increase of repair of
sublethal lesions. Int J Oncol. 24:1027–1031. 2004.
|
|
8.
|
Franken NAP, van Bree C, Veltmaat MA,
Ludwików G, Kipp JB and Barendsen GW: Increased chromosome exchange
frequencies in iodo-deoxyuridine-sensitized human SW-1573 cells
after γ-irradiation. Oncol Rep. 6:59–63. 1999.PubMed/NCBI
|
|
9.
|
Franken NAP, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nature
Protoc. 1:2315–2319. 2006. View Article : Google Scholar
|
|
10.
|
van Nifterik KA, van den Berg J, Stalpers
LJA, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ and Sminia P:
Differential radiosensitizing potential of temozolomide in MGMT
promoter methylated glioblastoma multiforme cell lines. Int J
Radiat Oncol Biol Phys. 69:1246–1253. 2007.PubMed/NCBI
|
|
11.
|
van Bree C, Franken NAP, Bakker PJ,
Klomp-Tukker LJ, Barendsen GW and Kipp JB: Hyperthermia and
incorporation of halogenated pyrimidines: radiosensitization in
cultured rodent and human tumor cells. Int J Radiat Oncol Biol
Phys. 39:489–496. 1997.PubMed/NCBI
|
|
12.
|
González González D, Van Dijk JD and Blank
LE: Radiotherapy and hyperthermia. Eur J Cancer. 31A:1351–1355.
1995.
|
|
13.
|
van der Zee J, González González D, van
Rhoon GC, van Dijk JD, van Putten WL and Hart AA: Comparison of
radiotherapy alone with radiotherapy plus hyperthermia in locally
advanced pelvic tumours: a prospective, randomised, multicentre
trial. Dutch Deep Hyperthermia Group. Lancet. 355:1119–1125.
2000.
|
|
14.
|
van der Zee J, Treurniet-Donker AD, The
SK, Helle PA, Seldenrath JJ, Meerwaldt JH, Wijnmalen AJ, van de
Berg AP, van Rhoon GC, Broekmeyer-Reurink MP, et al: Low dose
reirradiation in combination with hyperthermia: a palliative
treatment for patients with breast cancer recurring in previously
irradiated areas. Int J Radiat Oncol Biol Phys. 15:1407–1413.
1988.PubMed/NCBI
|
|
15.
|
van der Zee J and González GD: The Dutch
Deep Hyperthermia Trial: results in cervical cancer. Int J
Hyperthermia. 18:1–12. 2002.Erratum in: Int J Hyperthermia 19:213,
2003.
|
|
16.
|
Crezee J, Barendsen GW, Westermann AM,
Hulshof MC, Haveman J, Stalpers LJ, Geijsen ED and Franken NAP:
Quantification of the contribution of hyperthermia to results of
cervical cancer trials: in regard to Plataniotis and Dale (Int J
Radiat Oncol Biol Phys 73: 1538–1544, 2009). Int J Radiat Oncol
Biol Phys. 75:6342009.PubMed/NCBI
|
|
17.
|
Dewey WC, Sapareto SA and Betten DA:
Hyperthermic radio-sensitization of synchronous Chinese hamster
cells: relationship between lethality and chromosomal aberrations.
Radiat Res. 76:48–59. 1978. View Article : Google Scholar
|
|
18.
|
Roti Roti JL: Introduction:
radiosensitization by hyperthermia. Int J Hyperthermia. 20:109–114.
2004.PubMed/NCBI
|
|
19.
|
Raaphorst GP, Feeley MM, Danjoux CE,
DaSilva V and Gerig LH: Hyperthermia enhancement of radiation
response and inhibition of recovery from radiation damage in human
glioma cells. Int J Hyperthermia. 7:629–641. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kampinga HH and Dikomey E: Hyperthermic
radiosensitization: mode of action and clinical relevance. Int J
Radiat Biol. 77:399–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hildebrandt B, Wust P, Ahlers O, Dieing A,
Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and
molecular basis of hyperthermia. Crit Rev Oncol Hematol. 43:33–56.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hall EJ and Giaccia AJ: Hyperthermia.
Radiobiology for the Radiologist. Chapter 28.6th edition.
Lippincott Williams & Wilkins; Philadelphia, PA: pp. 469–490.
2006
|
|
23.
|
Dewhirst MW, Vujaskovic Z, Jones E and
Thrall D: Re-setting the biologic rationale for thermal therapy.
Int J Hyperthermia. 21:779–790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Bergs JWJ: Hyperthermia, cisplatin and
radiation trimodality treatment: In vitro studies on interaction
mechanisms. PhD Thesis, University of Amsterdam. 2007
|
|
25.
|
Bergs JWJ, Haveman J, Ten Cate R, Medema
JP, Franken NAP and van Bree C: Effect of 41°C and 43°C on
cisplatin radio-sensitization in two human carcinoma cell lines
with different sensitivities for cisplatin. Oncol Rep. 18:219–226.
2007.
|
|
26.
|
Bergs JWJ, Franken NAP, Haveman J, Geijsen
ED, Crezee J and van Bree C: Hyperthermia, cisplatin and radiation
trimodality treatment: a promising cancer treatment? A review from
preclinical studies to clinical application. Int J Hyperthermia.
23:329–341. 2007. View Article : Google Scholar
|
|
27.
|
Krawczyk PM, Eppink B, Essers J, Stap J,
Rodermond H, Odijk H, Zelensky A, van Bree C, Stalpers LJ, Buist
MR, Soullié T, Rens J, Verhagen HJ, O’Connor MJ, Franken NAP, Ten
Hagen TL, Kanaar R and Aten JA: Mild hyperthermia inhibits
homologous recombination, induces BRCA2 degradation, and sensitizes
cancer cells to poly(ADP-ribose) polymerase-1 inhibition. Proc Natl
Acad Sci USA. 108:9851–9856. 2011. View Article : Google Scholar
|
|
28.
|
Franken NAP, van Bree C, Ten Cate R, van
Oven CH and Haveman J: Importance of TP53 and RB in the repair of
potentially lethal damage and induction of color junctions after
exposure to ionizing radiation. Radiat Res. 158:707–714. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Gorodetsky R, Levy-Agababa F, Mou X and
Vexler AM: Combination of cisplatin and radiation in cell culture:
effect of duration of exposure to drug and timing of irradiation.
Int J Cancer. 75:635–642. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Dueñas-Gonzalez A, Cetina L, Mariscal I
and de la Garza J: Modern management of locally advanced cervical
carcinoma. Cancer Treat Rev. 29:389–399. 2003.
|
|
31.
|
Loprevite M, Favoni RE, de Cupis A, Pirani
P, Pietra G, Bruno S, Grossi F, Scolaro T and Ardizzoni A:
Interaction between novel anticancer agents and radiation in
non-small cell lung cancer cell lines. Lung Cancer. 33:27–39. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Begg AC, van der Kolk PJ, Dewit L and
Bartelink H: Radiosensitization by cisplatin of RIF1 tumour cells
in vitro. Int J Radiat Biol Relat Stud Phys Chem Med. 50:871–884.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Nakamoto S, Mitsuhashi N, Takahashi T,
Sakurai H and Niibe H: An interaction of cisplatin and radiation in
two rat yolk sac tumour cell lines with different
radiosensitivities in vitro. Int J Radiat Biol. 70:747–753. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Bergs JWJ, Franken NAP, Ten Cate R, van
Bree C and Haveman J: Effects of cisplatin and gamma-irradiation on
cell survival, the induction of chromosomal aberrations and
apoptosis in SW-1573 cells. Mutat Res. 594:148–154. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Fehlauer F, Barten-Van Rijbroek AD,
Stalpers LJ, Leenstra S, Lindeman J, Tjahja I, Troost D, Wolbers
JG, van der Valk P and Sminia P: Additive cytotoxic effect of
cisplatin and X-irradiation on human glioma cell cultures derived
from biopsy-tissue. J Cancer Res Clin Oncol. 126:711–716. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Crul M, van Waardenburg RC, Beijnen JH and
Schellens JH: DNA-based drug interactions of cisplatin. Cancer
Treat Rev. 28:291–303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Myint WK, Ng C and Raaphorst GP: Examining
the nonhomologous repair process following cisplatin and radiation
treatments. Int J Radiat Biol. 78:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Lawrence TS, Blackstock AW and McGinn C:
The mechanism of action of radiosensitization of conventional
chemotherapeutic agents. Semin Radiat Oncol. 13:13–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Haveman J, Castro Kreder N, Rodermond HM,
van Bree C, Franken NAP, Stalpers LJ, Zdzienicka MZ and Peters GJ:
Cellular response of X-ray sensitive hamster mutant cell lines to
gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep. 12:187–192.
2004.PubMed/NCBI
|
|
41.
|
De Silva IU, McHugh PJ, Clingen PH and
Hartley JA: Defects in interstrand cross-link uncoupling do not
account for the extreme sensitivity of ERCC1 and XPF cells to
cisplatin. Nucleic Acids Res. 30:3848–3856. 2002.PubMed/NCBI
|
|
42.
|
Dronkert ML and Kanaar R: Repair of DNA
interstrand cross-links. Mutat Res. 486:217–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Dolling JA, Boreham DR, Brown DL,
Raaphorst GP and Mitchel RE: Cisplatin-modification of DNA repair
and ionizing radiation lethality in yeast, Saccharomyces
cerevisiae. Mutat Res. 433:127–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Fossella FV, Lipmann SM, Shin DM,
Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK,
Glisson B, Rivera E and Hong WK: Maximum-tolerated dose defined for
single-agent gemcitabine: a phase I dose-escalation study in
chemotherapy-naive patients with advanced non-small-cell lung
cancer. J Clin Oncol. 15:310–316. 1997.PubMed/NCBI
|
|
45.
|
Manegold C, Zatloukal P, Krejcy K and
Blatter J: Gemcitabine in non-small lung cancer (NSCLC). Invest New
Drugs. 18:29–42. 2000. View Article : Google Scholar
|
|
46.
|
Shewach DS and Lawrence TS: Gemcitabine
and radiosensitization in human tumor cells. Invest New Drugs.
14:257–263. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Castro Kreder N, van Bree C, Franken NAP
and Havenman J: Effects of gemcitabine on cell survival and
chromosome aberrations after pulsed low dose-rate irradiation. J
Radiat Res. 45:111–118. 2004.PubMed/NCBI
|
|
48.
|
Heinemann V, Xu YZ, Chubb S, Sen A, Hertel
LW, Grindey GB and Plunkett W: Cellular elimination of
2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of
self-potentiation. Cancer Res. 52:533–539. 1992.
|
|
49.
|
Shewach DS, Hahn TM, Chang E, Hertel LW
and Lawrence TS: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and
radiation sensitization of human colon carcinoma cells. Cancer Res.
54:3218–3223. 1994.
|
|
50.
|
Plunkett W, Huang P and Gandhi V:
Preclinical characteristics of gemcitabine. Anticancer Drugs.
6(Suppl 6): 7–13. 1995. View Article : Google Scholar
|
|
51.
|
Auer H, Oehler R, Lindner R, Kowalski H,
Sliutz G, Orel L, Kucera E, Simon MM and Glössl J: Characterisation
of genotoxic properties of 2′,2′-difluorodeoxycytidine. Mutat Res.
393:165–173. 1997.
|
|
52.
|
Rockwell S and Grindey GB: Effect of
2′,2′-difluorodeoxycytidine on the viability and radiosensitivity
of EMT6 cells in vitro. Oncol Res. 4:151–155. 1992.
|
|
53.
|
Shewach DS and Lawrence TS:
Radiosensitization of human solid tumor cell lines with
gemcitabine. Semin Oncol. 23(Suppl 10): 65–71. 1996.PubMed/NCBI
|
|
54.
|
Latz D, Fleckenstein K, Eble M, Blatter J,
Wannenmacher M and Weber KJ: Radiosensitizing potential of
gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle
in vitro. Int J Radiat Oncol Biol Phys. 41:875–882. 1998.
|
|
55.
|
Gregoire V, Hittelman WN, Rosier JF and
Milas L: Chemoradiotherapy: Radiosensitizing nucleoside analogues
(Review). Oncol Rep. 6:949–957. 1999.PubMed/NCBI
|
|
56.
|
Milas L, Fujii T, Hunter N, Elshaikh M,
Mason K, Plunkett W, Ang KK and Hittelman W: Enhancement of tumor
radioresponse in vivo by gemcitabine. Cancer Res. 59:107–114.
1999.PubMed/NCBI
|
|
57.
|
van Putten JWG, Groen HJM, Smid K, Peters
GJ and Kampinga HH: End-joining deficiency and radiosensitization
induced by gemcitabine. Cancer Res. 61:1585–1591. 2001.PubMed/NCBI
|
|
58.
|
Wachters FM, van Putten JWG, Maring JG,
Zdzienicka MZ, Groen HJ and Kampinga HH: Selective targeting of
homologous DNA recombination repair by gemcitabine. Int J Radiat
Oncol Biol Phys. 57:553–562. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Castro Kreder N, van Bree C, Franken NAP
and Haveman J: Colour junctions as predictors of radiosensitivity:
X-irradiation combined with gemcitabine in a lung carcinoma cell
line. J Cancer Res Clin Oncol. 129:597–603. 2003.PubMed/NCBI
|
|
60.
|
Scalliet P, Goor C, Galdermans J, et al:
Gemzar (gemcitabine) with thoracic radiotherapy - a phase II pilot
study in chemo-naive patients with advanced non-small-cell lung
cancer (NSCLC) (Abstract). Proc ASCO. 17:499a1998.
|
|
61.
|
Blackstock AW, Lesser GJ, Fletcher-Steede
J, Case LD, Tucker RW, Russo SM, White DR and Miller A: Phase I
study of twice-weekly gemcitabine and concurrent thoracic radiation
for patients with locally advanced non-small cell lung cancer. Int
J Radiat Oncol Biol Phys. 51:1281–1289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Bergman AM, Giaccone G, van Moorsel CJ,
Mauritz R, Noordhuis P, Pinedo HM and Peters GJ: Cross-resistance
in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human
ovarian cancer cell line AG6000 to standard and investigational
drugs. Eur J Cancer. 36:1974–1983. 2000.
|
|
63.
|
Bergman AM, Pinedo HM, Jongsma AP, Brouwer
M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S and Peters
GJ: Decreased resistance to gemcitabine
(2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant
myeloblastic murine and rat leukemia cell lines: role of altered
activity and substrate specificity of deoxycytidine kinase. Biochem
Pharmacol. 57:397–406. 1999.
|
|
64.
|
van Bree C, Castro Kreder N, Loves WJ,
Franken NAP, Peters GJ and Haveman J: Sensitivity to ionizing
radiation and chemotherapeutic agents in gemcitabine-resistant
human tumor cell lines. Int J Radiat Oncol Biol Phys. 54:237–244.
2002.PubMed/NCBI
|
|
65.
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO; European
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups; National Cancer Institute of Canada Clinical
Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466.
2009.
|
|
67.
|
Hegi ME, Diserens AC, Godard S, Dietrich
PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N and
Stupp R: Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin Cancer Res.
10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and
Stupp R: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Brennand J and Margison GP: Reduction of
the toxicity and mutagenicity of alkylating agents in mammalian
cells harboring the Escherichia coli alkyltransferase gene.
Proc Natl Acad Sci USA. 83:6292–6296. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Wedge SR, Porteus JK, May BL and Newlands
ES: Potentiation of temozolomide and BCNU cytotoxicity by
O(6)-benzylguanine: a comparative study in vitro. Br J Cancer.
73:482–490. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Karran P, Macpherson P, Ceccotti S,
Ceccotti S, Dogliotti E, Griffin S and Bignami M:
O6-methylguanine residues elicit DNA repair synthesis by
human cell extracts. J Biol Chem. 268:15878–15886. 1993.
|
|
72.
|
Ochs K and Kaina B: Apoptosis induced by
DNA damage O6-methylguanine is Bcl-2 and caspase-9/3
regulated and Fas/caspase-8 independent. Cancer Res. 60:5815–5824.
2000.PubMed/NCBI
|
|
73.
|
Gerson SL: MGMT: its role in cancer
aetiology and cancer therapeutics. Nat Rev Cancer. 4:296–307. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Hotta T, Saito Y, Fujita H, Mikami T,
Kurisu K, Kiya K, Uozumi T, Isowa G, Ishizaki K and Ikenaga M:
O6-alkylguanine-DNA alkyltransferase activity of human
malignant glioma and its clinical implications. J Neurooncol.
21:135–140. 1994.
|
|
75.
|
Qian XC and Brent TP: Methylation hot
spots in the 5′ flanking region denote silencing of the
O6-methylguanine-DNA methyltransferase gene. Cancer Res.
57:3672–3677. 1997.
|
|
76.
|
Watts GS, Pieper RO, Costello JF, Peng YM,
Dalton WS and Futscher BW: Methylation of discrete regions of the
O6-methylguanine DNA methyltransferase (MGMT) CpG island
is associated with heterochromatinization of the MGMT transcription
start site and silencing of the gene. Mol Cell Biol. 17:5612–5619.
1997.PubMed/NCBI
|
|
77.
|
Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes
G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ,
Balaña C, Sanchez-Cespedes M, García-Villanueva M, Arribas L and
Esteller M: CpG island hypermethylation of the DNA repair enzyme
methyltransferase predicts response to temozolomide in primary
gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Donson AM, Addo-Yobo SO, Handler MH, Gore
L and Foreman NK: MGMT promoter methylation correlates with
survival benefit and sensitivity to temozolomide in pediatric
glioblastoma. Pediatr Blood Cancer. 48:403–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Chalmers AJ, Ruff EM, Martindale C,
Lovegrove N and Short SC: Cytotoxic effects of temozolomide and
radiation are additive- and schedule-dependent. Int J Radiat Oncol
Biol Phys. 75:1511–1519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar
|
|
81.
|
Chakravarti A, Erkkinen MG, Nestler U,
Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM and Loeffler JS:
Temozolomide-mediated radiation enhancement in glioblastoma: a
report on underlying mechanisms. Clin Cancer Res. 12:4738–4746.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
van Rijn J, Heimans JJ, van den Berg J,
van der Valk P and Slotman BJ: Survival of human glioma cells
treated with various combinations of temozolomide and X-rays. Int J
Radiat Oncol Biol Phys. 47:779–784. 2000.PubMed/NCBI
|
|
83.
|
Wedge SR, Porteous JK, Glaser MG, Marcus K
and Newlands ES: In vitro evaluation of temozolomide combined with
X-irradiation. Anticancer Drugs. 8:92–97. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
84.
|
van Nifterik KA, van den Berg J, van der
Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S,
Lafleur MV, Slotman BJ, Stalpers LJ and Sminia P: Absence of the
MGMT protein as well as methylation of the MGMT promoter predict
the sensitivity for temozolomide. Br J Cancer. 103:29–35.
2010.PubMed/NCBI
|
|
85.
|
van Nifterik KA, van den Berg J, Slotman
BJ, Lafleur MV, Sminia P and Stalpers LJ: Valproic acid sensitizes
human glioma cells for temozolomide and γ-radiation. J Neurooncol.
107:61–67. 2012.
|
|
86.
|
Franken NAP, van Bree C, Streefkerk J,
Kuper I, Rodermond H, Kipp JB and Barendsen GW: Radiosensitization
by iodo-deoxyuridine in cultured SW-1573 human lung tumor cells:
Effects on α and β of the linear-quadratic model. Oncol Rep.
4:1073–1076. 1997.PubMed/NCBI
|
|
87.
|
Franken NAP, Ruurs P, Ludwików G, van Bree
C, Kipp JB, Darroudi F and Barendsen GW: Correlation between cell
reproductive death and chromosome aberrations assessed by FISH for
low and high doses of radiation and sensitization by
iododeoxyuridine in human SW-1573 cells. Int J Radiat Biol.
75:293–299. 1999. View Article : Google Scholar
|
|
88.
|
Iliakis G, Kurtzman S, Pantelias G and
Okayasu R: Mechanism of radiosensitisation by halogenated
pyrimidines: effect of BrdU on radiation induction of DNA and
chromosome damage and its correlation with cell killing. Radiat
Res. 119:286–304. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
89.
|
Iliakis G, Wang Y, Pantelias GE and
Metzger L: Mechanism of radiosensitisation of halogenated
pyrimidines: effect of BrdU on repair of DNA breaks, interphase
chromatin breaks and potentially lethal damage in plateau-phase CHO
cells. Radiat Res. 129:202–211. 1992. View Article : Google Scholar
|
|
90.
|
Iliakis G, Wright E and Ngo FQ: Possible
importance of PLD repair in the modulation of BrdUrd and
IdUrd-mediated radiosensitisation in plateau-phase C3H10T1/2 mouse
embryo cells. Int J Radiat Biol Relat Stud Phys Chem Med.
51:541–548. 1987. View Article : Google Scholar
|
|
91.
|
Iliakis G, Pantelias G and Kurtzman S:
Mechanism of radiosensitisation by halogenated pyrimidines: effect
of BrdU on cell killing and interphase chromosome breakage in
radiation-sensitive cells. Radiat Res. 25:56–64. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
92.
|
Miller EM, Fowler JF and Kinsella TJ:
Linear-quadratic analysis of radiosensitisation by halogenated
pyrimidines. I Radiosensitisation of human colon cancer cells by
iododeoxyuridine. Radiat Res. 131:81–89. 1992. View Article : Google Scholar
|
|
93.
|
Miller EM, Fowler JF and Kinsella TJ:
Linear-quadratic analysis of radiosensitisation by halogenated
pyrimidines. II Radiosensitisation of human colon cancer cells by
bromodeoxyuridine. Radiat Res. 131:90–97. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
94.
|
Jones GD, Ward JF, Limoli CL, Moyer DJ and
Aguilera JA: Mechanisms of radiosensitization in
iododeoxyuridine-substituted cells. Int J Radiat Biol. 67:647–653.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
95.
|
Bouchard VJ, Rouleau M and Poirier GG:
PARP-1, a determinant of cell survival in response to DNA damage.
Exp Hematol. 31:446–454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
96.
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97.
|
Löser DA, Shibata A, Shibata AK, Woodbine
LJ, Jeggo PA and Chalmers AJ: Sensitization to radiation and
alkylating agents by inhibitors of poly(ADP-ribose) polymerase is
enhanced in cells deficient in DNA double-strand break repair. Mol
Cancer Ther. 9:1775–1787. 2010.PubMed/NCBI
|
|
98.
|
Cate RT, Krawczyk P, Stap J, Aten JA and
Franken NAP: Radiosensitizing effect of the histone
acetyltransferase inhibitor anacardic acid on various mammalian
cell lines. Oncol Lett. 1:765–769. 2010.PubMed/NCBI
|
|
99.
|
Rodermond HM, Ten Cate R, Haveman J, van
Kuilenburg A, Medema JP, van Bree C and Franken NAP:
Cyclopentenylcytosine does not enhance cisplatin-induced
radiosensitization in human lung tumour cells. Oncol Lett.
1:537–540. 2010.PubMed/NCBI
|
|
100.
|
Ryu S, Brown SL, Kim SH, Khil MS and Kim
JH: Preferential radiosensitization of human prostatic carcinoma
cells by mild hyperthermia. Int J Radiat Oncol Biol Phys.
34:133–138. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
101.
|
Bergs JWJ, Ten Cate R, Haveman J, Medema
JP, Franken NAP and van Bree C: Chromosome fragments have the
potential to predict hyperthermia-induced radio-sensitization in
two different human tumor cell lines. J Radiat Res. 49:465–472.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
102.
|
van Bree C, Savonije JH, Franken NAP,
Haveman J and Bakker PJ: The effect of p53-function on the
sensitivity to paclitaxel with or without hyperthermia in human
colorectal carcinoma cells. Int J Oncol. 16:739–744.
2000.PubMed/NCBI
|
|
103.
|
van Bree C, van der Maat B, Ceha HM,
Franken NAP, Haveman J and Bakker PJ: Inactivation of p53 and of
pRb protects human colorectal carcinoma cells against
hyperthermia-induced cytotoxicity and apoptosis. J Cancer Res Clin
Oncol. 125:549–555. 1992.PubMed/NCBI
|
|
104.
|
Larsson C and Ng CE: p21+/+
(CDKN1A+/+) and p21−/− (CDKN1A−/−)
human colorectal carcinoma cells display equivalent amounts of
thermal radiosensitization. Radiat Res. 160:205–209. 2003.
|
|
105.
|
Murthy AK, Harris JR and Belli JA:
Hyperthermia and radiation response of plateau phase cells.
Potentiation and radiation damage repair. Radiat Res. 70:241–247.
1977. View Article : Google Scholar : PubMed/NCBI
|
|
106.
|
Xu M, Myerson RJ, Xia Y, Whitehead T,
Moros EG, Straube WL and Roti Roti JL: The effects of 41 degrees C
hyperthermia on the DNA repair protein, MRE11, correlate with
radiosensitization in four human tumor cell lines. Int J
Hyperthermia. 23:343–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107.
|
Xu M, Wright WD, Higashikubo R, Wang LL
and Roti Roti JL: Thermal radiosensitization of human tumour cell
lines with different sensitivities to 41.1 degrees C. Int J
Hyperthermia. 15:279–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
108.
|
Vujaskovic Z and Song CW: Physiological
mechanisms underlying heat-induced radiosensitization. Int J
Hyperthermia. 20:163–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
109.
|
Oleson JR: Eugene Robertson Special
Lecture. Hyperthermia from the clinic to the laboratory: a
hypothesis. Int J Hyperthermia. 11:315–322. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
110.
|
Song CW, Shakil A, Osborn JL and Iwata K:
Tumour oxygenation is increased by hyperthermia at mild
temperatures. Int J Hyperthermia. 12:367–373. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
111.
|
Xu M, Myerson RJ, Straube WL, Moros EG,
Lagroye I, Wang LL, Lee JT and Roti Roti JL: Radiosensitization of
heat resistant human tumour cells by 1 hour at 41.1 degrees C and
its effect on DNA repair. Int J Hyperthermia. 18:385–403. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
112.
|
Mackey MA and Ianzini F: Enhancement of
radiation-induced mitotic catastrophe by moderate hyperthermia. Int
J Radiat Biol. 76:273–280. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
113.
|
Wilkins DE, Ng CE and Raaphorst GP:
Cisplatin and low dose rate irradiation in cisplatin resistant and
sensitive human glioma cells. Int J Radiat Oncol Biol Phys.
36:105–111. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
114.
|
Wilkins DE, Heller DP and Raaphorst GP:
Inhibition of potentially lethal damage recovery by cisplatin in a
brain tumor cell line. Anticancer Res. 13:2137–2142.
1993.PubMed/NCBI
|
|
115.
|
Huang H, Huang SY, Chen TT, Chen JC, Chiou
CL and Huang TM: Cisplatin restores p53 function and enhances the
radiosensitivity in HPV16 E6 containing SiHa cells. J Cell Biochem.
91:756–765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
116.
|
Britten RA, Peacock J and Warenius HM:
Collateral resistance to photon and neutron irradiation is
associated with acquired cis-platinum resistance in human ovarian
tumour cells. Radiother Oncol. 23:170–175. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
117.
|
Britten RA, Evans AJ, Allalunis-Turner MJ
and Pearcey RG: Effect of cisplatin on the clinically relevant
radiosensitivity of human cervical carcinoma cell lines. Int J
Radiat Oncol Biol Phys. 34:367–374. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
118.
|
Monk BJ, Burger RA, Parker R, Radany EH,
Redpath L and Fruehauf JP: Development of an in vitro
chemo-radiation response assay for cervical carcinoma. Gynecol
Oncol. 87:193–199. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
119.
|
Meyn RE, Meistrich ML and White RA:
Cycle-dependent anticancer drug cytotoxicity in mammalian cells
synchronized by centrifugal elutriation. J Natl Cancer Inst.
64:1215–1219. 1980.PubMed/NCBI
|
|
120.
|
Krishnaswamy G and Dewey WC: Cisplatin
induced cell killing and chromosomal aberrations in CHO cells:
treated during G1 or S phase. Mutat Res. 293:161–172. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
121.
|
Turchi JJ, Henkels KM and Zhou Y:
Cisplatin-DNA adducts inhibit translocation of the Ku subunits of
DNA-PK. Nucleic Acids Res. 28:4634–4641. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
122.
|
Muggia FM and Fojo T: Platinums: extending
their therapeutic spectrum. J Chemother. 16(Suppl 4): 77–82. 2004.
View Article : Google Scholar
|
|
123.
|
Dewit L: Combined treatment of radiation
and cisdiamminedichloroplatinum (II): a review of experimental and
clinical data. Int J Radiat Oncol Biol Phys. 13:403–426. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
124.
|
Kumala S, Niemiec P, Widel M, Hancock R
and Rzeszowska-Wolny J: Apoptosis and clonogenic survival in three
tumour cell lines exposed to gamma rays or chemical genotoxic
agents. Cell Mol Biol Lett. 8:655–665. 2003.PubMed/NCBI
|
|
125.
|
Guchelaar HJ, Vermes I, Koopmans RP,
Reutelingsperger CP and Haanen C: Apoptosis- and necrosis-inducing
potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil
in vitro: a quantitative pharmacodynamic model. Cancer Chemother
Pharmacol. 42:77–83. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
126.
|
Fujita M, Fujita T, Kodama T, Tsuchida T
and Higashino K: The inhibitory effect of cisplatin in combination
with irradiation on lung tumor cell growth is due to induction of
tumor cell apoptosis. Int J Oncol. 17:393–397. 2000.PubMed/NCBI
|
|
127.
|
Ostruszka LJ and Shewach DS: The role of
cell cycle progression in radiosensitization by
2′,2′-difluoro-2′-deoxycytidine. Cancer Res. 60:6080–6088.
2000.
|
|
128.
|
Ruiz van Haperen VW, Veerman G, Eriksson
S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM and
Peters GJ: Development and molecular characterization of a
2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian
carcinoma cell line A2780. Cancer Res. 54:4138–4143. 1994.
|
|
129.
|
Peters GJ, Ruiz van Haperen VW, Bergman
AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM and
Braakhuis BJ: Preclinical combination therapy with gemcitabine and
mechanisms of resistance. Sem Oncology. 23(Suppl 10): 16–24.
1996.PubMed/NCBI
|
|
130.
|
Wang Y, Pantelias GE and Iliakis G:
Mechanism of radiosensitization by halogenated pyrimidines: the
contribution of excess DNA and chromosome damage in BrdU
radiosensitization may be minimal in plateau-phase cells. Int J
Radiat Biol. 66:133–142. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
131.
|
Webb CF, Jones GD, Ward JF, Moyer DJ,
Aguilera JA and Ling LL: Mechanisms of radiosensitisation in
bromodeoxyuridine-substituted cells. Int J Radiat Biol. 64:695–705.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
132.
|
Albert JM, Cao C, Kim KW, Willey CD, Geng
L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J,
Rothenberg ML and Lu B: Inhibition of poly(ADP-ribose) polymerase
enhances cell death and improves tumor growth delay in irradiated
lung cancer models. Clin Cancer Res. 13:3033–3042. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
133.
|
Douglas BG and Fowler JF: The effect of
multiple small doses of x-rays on skin reactions in the mouse and a
basic interpretation. Radiat Res. 66:401–426. 1976. View Article : Google Scholar
|
